Your browser doesn't support javascript.
loading
Topical treatments for early-stage mycosis fungoides using Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria: A systematic review.
Wennberg, Ebba; Richards, Phillip Q; Bain, Paul A; Huang, Victor; Sullivan, Sydney D; Maverakis, Emanual M; Molina, Gabriel E; Wu, Peggy A.
Afiliação
  • Wennberg E; Haematology Department, Kings College Hospital, London, United Kingdom.
  • Richards PQ; Boston University School of Medicine, Boston, Massachussetts.
  • Bain PA; Countway Library of Medicine, Harvard Medical School, Boston, Massachussetts.
  • Huang V; Department of Dermatology, University of California, Davis, Sacramento, California.
  • Sullivan SD; Department of Dermatology, University of California, Davis, Sacramento, California.
  • Maverakis EM; Department of Dermatology, University of California, Davis, Sacramento, California.
  • Molina GE; Harvard Medical School, Boston, Massachussetts.
  • Wu PA; Department of Dermatology, University of California, Davis, Sacramento, California.
JAAD Int ; 3: 26-41, 2021 Jun.
Article em En | MEDLINE | ID: mdl-34409369
BACKGROUND: Mycosis fungoides (MF) is a cutaneous lymphoma; most patients present with early, skin-limited disease and are managed by dermatologists. OBJECTIVE: The purpose of this study was to systematically review and assess the evidence on topical treatments for early-stage (IA, IB, IIA) MF. METHODS: We performed a literature search via MEDLINE, Embase, Web of Science, and Cochrane databases. Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria were used to assess the certainty of the data. RESULTS: Two searches yielded 1252 references; 26 met the inclusion criteria and included literature on nitrogen mustard, retinoids, corticosteroids, carmustine, fluorouracil, methotrexate-laurocapram, hexadecylphosphocholine, peldesine, ingenol mebutate, topical methotrexate with oxygen flow-assisted LP3 carrier, and resiquimod. Most studies were single intervention, observational series. Nitrogen mustard, with the most published reports, was effective with 12%-82% early-stage MF patients (total n > 1000) achieving complete remission (CR) (low certainty evidence). Clinical CR was achieved among 10%-60% treated with topical retinoids (low certainty evidence). Two moderate-sized retrospective case series on topical steroids had 18%-63% CR (low certainty evidence). Only single studies were available for the other therapies. CONCLUSIONS: For most outcomes of interest, the GRADE certainty for topical therapies for early-stage MF was low. Further randomized controlled trials and inclusion of quality of life indicators are needed.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Systematic_reviews Idioma: En Revista: JAAD Int Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Systematic_reviews Idioma: En Revista: JAAD Int Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido